COST-EFFECTIVENESS ANALYSIS OF ANTIBIOTIC USAGE IN DIABETIC FOOT ULCUS PATIENTS IN DOKTER SOEKARDJO TASIKMALAYA HOSPITAL

NUR RAHAYUNINGSIH; ALLFI LAILLA PRATIWI; ANISA PEBIANSYAH

doi:10.22159/ijap.2022.v14s5.25

Authors

NUR RAHAYUNINGSIH Department of Pharmacy, University of Bakti Tunas Husada, Jl. Cilolohan No. 36, Jawa Barat 46115
ALLFI LAILLA PRATIWI Department of Pharmacy, University of Bakti Tunas Husada, Jl. Cilolohan No. 36, Jawa Barat 46115
ANISA PEBIANSYAH Department of Pharmacy, University of Bakti Tunas Husada, Jl. Cilolohan No. 36, Jawa Barat 46115

DOI:

https://doi.org/10.22159/ijap.2022.v14s5.25

Keywords:

Antibiotics, Cost-effectiveness analysis, Diabetic foot ulcus

Abstract

Objective: Diabetic foot ulcers is sores on the skin surface until it penetrates the skin layer caused by infection, which is require high costs for treatment. This puts a considerable burden on the patient's family, health agencies and society in general. The purpose of this study was to describe the direct medical costs and cost-effective antibiotics for diabetic foot ulcer patients at Dokter Soekardjo Tasikmalaya Hospital.

Methods: The research method is retrospectively with a purposive sampling technique. The research subjects included 24 hospitalized diabetic foot ulcer patients who received antibiotic treatment ceftriaxone with metronidazole or meropenem with metronidazole. The effectiveness of therapy was determined by the Length of Stay (LOS). Direct medical costs were obtained from medical costs, treatment costs, laboratory costs, and radiology costs.

Results: The average direct medical cost for the combination of ceftriaxone and metronidazole antibiotics was Rp. 4 668 062 and for the combination of meropenem antibiotics with metronidazole was Rp. 9 093 830. The effectiveness of the antibiotic ceftriaxone with metronidazole was 47%.

Conclusion: The cost-effective antibiotic was ceftriaxone with metronidazole which has the lowest ACER value Rp. 9 932 046 and the ICER value is Rp. 22 128 840.

Downloads

Download data is not yet available.

References

Ibrahim A, Jude E, Langton K. IDF clinical practice recommendations on the diabetic foot–2017; 2017. doi: 10.1016/j.diabres.2017.09.002.

Sari YO, Almasdy D, Fatimah A. Evaluasi penggunaan antibiotik pada pasien ulkus diabetikum di instalasi rawat inap (IRNA) penyakit dalam RSUP Dr. M. Djamil padang. J Sains Farm Klin. 2018;5(2):102-11. doi: 10.25077/jsfk.5.2.102-111.2018.

Oktorina R, Wahyuni A, Harahap EY. Faktor-faktor yang berhubungan dengan perilaku pencegahan ulkus diabetikum pada penderita diabetes mellitus. Real in Nursing Journal 2019;2(3):108. doi: 10.32883/rnj.v2i3.570.

Kartika RW. Pengelolaan gangren kaki diabetik. Cermin Dunia Kedokt. 2017;44(1):18-22.

Jakosz N. Book review–IWGDF guidelines on the prevention and management of diabetic foot disease. WPR. 2019;27(3). doi: 10.33235/wpr.27.3.144.

Cheng Q, Lazzarini PA, Gibb M, Derhy PH, Kinnear EM, Burn E. A cost-effectiveness analysis of optimal care for diabetic foot ulcers in Australia. Int Wound J. 2017;14(4):616-28. doi: 10.1111/iwj.12653, PMID 27489228.

Lipsky BA, Senneville E, Abbas ZG. IWGDF guideline on the diagnosis and treatment of foot infection in persons with diabetes. IWGDF Guidel Publ Online. 2019:1-43.

Woods TJ, Tesfay F, Speck P, Kaambwa B. Economic evaluations considering costs and outcomes of diabetic foot ulcer infections: a systematic review. PLOS ONE. 2020;15(4):e0232395. doi: 10.1371/journal.pone.0232395. PMID 32353082.

Tjandrawinata RR. Peran farmaekonomi dalam penentuan kebijakan yang berkaitan dengan obat-obatan. Work Pap Dexa Med Gr. 2016;29(1):46-52.

Muennig P, Bounthavong M. Cost-effectiveness analysis in health: A practical approach; 2016.

Khoiriyah SD, Lestari K. Review artikel: kajian farmakoekonomi yang mendasari pemilihan pengobatan di Indonesia. Farmaka. 2019;16(3):134-45. doi: 10.24123/mpi.v2i2.1391.

Harreiter J, Kautzky Willer A. Sex and gender differences in prevention of type 2 diabetes. Front Endocrinol (Lausanne). 2018;9:220. doi: 10.3389/fendo.2018.00220, PMID 29780358.

Isnaini N, Ratnasari R. Faktor risiko mempengaruhi kejadian diabetes mellitus Tipe Dua. JKK. 2018;14(1):59-68. doi: 10.31101/jkk.550.

Suba Z. Low estrogen exposure and/or defective estrogen signaling induces disturbances in glucose uptake and energy expenditure. J Diabetes Metab. 2013;4(5). doi: 10.4172/2155-6156.1000272.

Anggowarsito JL, Kulit AFP. WIdiya. Med, (Surabaya). 2014;2(1):56-61.

Kesehatan TJ. Presiden republik Indonesia. Peraturan Presiden RI Tahun 2018. Vol. 82; 2018. p. 2560-657X:74.

Tasikmalaya W. Tasikmalaya Nomor PW. 59 Tahun. 2011;2011:1-15.